Cytiva is a global technology and service provider committed to promoting unseen technologies and accelerating extraordinary therapies. Cytiva's long history goes back hundreds of years ago, becoming an independently operated company under the Danaher Group in 2020, and has embarked on a new journey.

From basic biological research to innovative vaccine research and development, from biomedicine to the development of new cell and gene therapies, the work of Cytiva Stufan’s clients is closely related to life. Cytiva's products and services provide strong support to customers, helping them accelerate research, reduce costs and increase efficiency, thereby benefiting patients around the world.

In 2020, most monoclonal antibodies approved by the U.S. Food and Drug Administration use Cytiva's technology during their production process. Cytiva takes pride in it and will continue to develop stable and reliable solutions to help more life-saving therapies.

Through replicable modern biotechnology technologies and cell and gene therapy facilities, Cytiva provides you with tools and expertise to advance research and introduce key therapies into the clinic.

Cytiva serves the production process of approved and registered biomedicine (including cell and gene therapy) with a steady stream of products. Cytiva Situfan always practices the concept of sustainable development and truly meets the needs of current patients without sacrificing the interests of future generations.